New Prognostic Markers in CLL
Open Access
- 1 January 2006
- journal article
- review article
- Published by American Society of Hematology in Hematology
- Vol. 2006 (1), 279-284
- https://doi.org/10.1182/asheducation-2006.1.279
Abstract
The individual prognosis of patients with chronic lymphocytic leukemia (CLL) is extremely variable. Although clinical stages remain the basis for assessing prognosis in CLL, a number of biological markers, particularly serum markers, cytogenetic abnormalities, IgVH mutations, CD38 and ZAP-70 expression in leukemic cells offer important, independent prognostic information. Before being incorporated into daily practice, however, these markers require standardization and validation in large, prospective trials. Meanwhile, treatment of patients with CLL not included in clinical studies should be decided on the basis of classical NCI/CLL Working Group criteria. An important area of research in CLL prognostication is the identification of markers useful for predicting response to therapy and its duration. Among them, del(17p), reflecting P53 abnormalities, is particularly important. Also relevant is del(11q), which points to ATM defects. There is also some correlation between IgVH mutational status, ZAP-70 and CD38 expression and response to therapy and its duration, although these relationships need further investigation. Finally, there is increasing evidence that response to therapy, particularly in those cases in which minimal residual disease is eradicated, is associated with longer survival.Keywords
This publication has 36 references indexed in Scilit:
- Risk Stratification in Chronic Lymphocytic LeukemiaSeminars in Oncology, 2006
- CD38 as a prognostic factor in B cell chronic lymphocytic leukaemia (B‐CLL): Comparison of three approaches to analyze its expressionCytometry Part B: Clinical Cytometry, 2006
- Chromosomal translocations are associated with poor prognosis in chronic lymphocytic leukemiaBlood, 2006
- Chemoimmunotherapy With Fludarabine, Cyclophosphamide, and Rituximab for Relapsed and Refractory Chronic Lymphocytic LeukemiaJournal of Clinical Oncology, 2005
- Early Results of a Chemoimmunotherapy Regimen of Fludarabine, Cyclophosphamide, and Rituximab As Initial Therapy for Chronic Lymphocytic LeukemiaJournal of Clinical Oncology, 2005
- Prognostic Usage of VH Gene Mutation Status and Its Surrogate Markers and the Role of Antigen Selection in Chronic Lymphocytic LeukemiaMedical Oncology, 2005
- Relation of Gene Expression Phenotype to Immunoglobulin Mutation Genotype in B Cell Chronic Lymphocytic LeukemiaThe Journal of Experimental Medicine, 2001
- Genomic Aberrations and Survival in Chronic Lymphocytic LeukemiaThe New England Journal of Medicine, 2000
- A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysisCancer, 1981
- Clinical staging of chronic lymphocytic leukemiaBlood, 1975